trending Market Intelligence /marketintelligence/en/news-insights/trending/J8ObrP5TOHNZ9i_5P23fMw2 content esgSubNav
In This List

Aclaris' Eskata wins FDA approval to treat non-cancerous skin growths

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Aclaris' Eskata wins FDA approval to treat non-cancerous skin growths

Aclaris Therapeutics Inc. said the U.S. Food and Drug Administration approved topical solution Eskata to treat non-cancerous skin growths.

Eskata is the first and only U.S. FDA approved topical, non-invasive treatment for the growths called raised seborrheic keratoses.

The company said the approval was based on two phase 3 trials that showed the safety and efficacy of Eskata. Patients treated with the medicine were more likely to have all four skin growths completely cleared after two treatments than patients who received placebo.

Eskata will be offered to patients as a self-pay aesthetic treatment and is expected to be commercially available in the spring of 2018.

Aclaris said it submitted a marketing authorization application for Eskata for treating seborrheic keratoses in select countries in the EU.